COVID-19 Video Series

Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) the risk and recommendations of the COVID-19 vaccine for myeloma and AL amyloidosis patients.

Dr Anna Sureda, Head of the Hematology Department, Instituto Catalán de oncología (ICO), in Spain, talks about COVID-19 vaccination for family members and caregivers.

Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) updates on the current approved vaccines in Europe and how they affect to myeloma and AL amyloidosis patients.

Several stem cell transplantations have been postponed during the COVID-19 outbreak. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains how these will restart.

Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) the word of advice she would give to patients participating in clinical trials druing the COVID-19 outbreak.

Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) the long term impact of COVID-19 outbreak on CAR-T treatment and trials.

Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains what the new normal will be for myeloma and AL amyloidosis patients.

Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) if is safe to participate in a CAR-T trial in myeloma during the COVID-19 outbreak

Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) the word of advice he would give to myeloma patients who are about to start a CAR-T clinical trial during the COVID-19 pandemic

The COVID-19 outbreak and the lockdown restrictions impacted on the treatment of myeloma patients. Watch Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains what changes were done in the treatment of myeloma patientes during the COVID-19 outbreak.

The situation in some European countries, like Spain or Italy, has been extremely difficult the last couple of months. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre and Marie Curie, Paris (France), explains his opinion about how ready National Health Systems are now to face second outbreak if it happens.

Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains possible implications of the changes in myeloma treatment during the COVID-19 outbreak.

Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) how academic and industry clinical trials, that have been postponed during COVID-19, will reopen in the coming months.

Recent data showed that dexamethasone, a drug used in most myeloma drug combinations, might be useful to treat COVID-19. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre and Marie Curie, Paris (France), explains the implications of it for myeloma patients.

Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) how the COVID-19 pandemic is affecting CAR-T myeloma clinical trials.